科研动态PubMed 摘要
Divarasib 优于第一代 KRASG12C 抑制剂。
PubMed 白名单日捞 · 2026-10-27
完整摘要 · 中文译文
一项国际III期试验得出结论：既往接受过治疗的KRAS G12C突变非小细胞肺癌患者，接受KRAS G12C抑制剂divarasib治疗者，其疾病复发或死亡风险比接受标准第一代药物sotorasib或adagrasib治疗者低42%。在中位随访14.3个月后，两组的中位无进展生存期分别为9.8个月和5.7个月。
完整摘要 · 英文原文
Patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received the KRASG12C inhibitor divarasib were 42% less likely to experience disease recurrence or die than those who received the standard first-generation drugs sotorasib or adagrasib, an international phase III trial concluded. After a median follow-up of 14.3 months, the median progression-free survival was 9.8 months and 5.7 months, respectively.
English
Divarasib Bests 1st-Generation KRASG12C Inhibitors.